Status:
COMPLETED
Rexon-Eye in Dry Eye
Lead Sponsor:
Singapore National Eye Centre
Conditions:
Dry Eye
Eligibility:
All Genders
21-70 years
Phase:
NA
Brief Summary
Resono Ophthalmic has developed Rexo-Eye in 2014, a QMR-based patented instrument which is hypothesised to stimulate physiological cellular regeneration and reactivate the tear system by stimulating a...
Detailed Description
Dry eye disease, or ocular surface disease (OSD)as defined by the International Dry Eye Workshop (2007)1, is a multifactorial disease of the tears and ocular surface that results in symptoms of discom...
Eligibility Criteria
Inclusion
- 21 years old and above;
- Diagnosed with moderate dry eyes based on grade 3 and worse corneal fluorescein staining in the central interpalpebral region
- Are on other eye drops (including artificial tears, topical ciclosporin, steroids), blephagel or lid warming solely for dry eyes, with no recent change in the last 1 month;
- Willing to perform all eye examinations in this study;
- Clear of exclusion criteria
Exclusion
- Pregnant women
- Patients carrying active implantable device (e.g., pacemakers and hearing aids)
- Oncologic patients under treatment
- Patient who underwent ocular surgery in the last month
- Patients who are vegan or exclude egg in their diet
- Patient who is on antibiotic or glaucoma eye drops
- Patient who had ocular infection within 6 months
- Any other specified reason as determined by clinical investigator
Key Trial Info
Start Date :
July 20 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 30 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04320563
Start Date
July 20 2019
End Date
August 30 2022
Last Update
October 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Singapore Eye Research Institute
Singapore, Singapore, 169856